Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
TXA in Anticoagulated Patients Study
NCT04560010 · NYU Langone Health · PHASE4 · terminated · last registry update 2024-03-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Enrollment rate was slower than anticipated” | – | Registry record, NYU Langone Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-25Results posted on the registry: George Washington University, Tranexamic Acid (NCT03287336)
- 2025-02-21Also stopped (withdrawn): Northwestern University, Tranexamic acid + Normal saline (NCT05554211)
- 2025-01-31Also stopped (withdrawn): The University of Texas Medical Branch, Galveston, Tranexamic acid + Vasopressin (NCT06419075)
- 2024-12-20Also stopped (terminated): St. Jude Children's Research Hospital, Tranexamic Acid (NCT04410042)
- 2024-12-13Also stopped (withdrawn): Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Tranexamic acid (TXA) (NCT05802238)
- 2024-12-05Results posted on the registry: St. Jude Children's Research Hospital, Tranexamic Acid (NCT04410042)
- 2024-11-27Phase 3 first posted: District Headquarters Teaching Hospital Sahiwal, Tranexamic Acid + Calcium dobesilate (Doxium) (NCT06707051)
- 2024-11-21Results posted on the registry: University of Missouri-Columbia, Tranexamic acid + normal saline (NCT04541303)
- 2024-11-19Also stopped (terminated): Riley McLean, Tranexamic acid injection + Lidocaine Epinephrine (NCT04630886)
- 2024-10-22Results posted on the registry: Wake Forest University Health Sciences, Tranexamic acid + Epsilon Aminocaproic Acid (NCT02656472)
- 2024-10-21Also stopped (terminated): University of Nove de Julho, a drug against PLG (NCT05326997)
- 2024-10-15Also stopped (withdrawn): University of Kansas Medical Center, Tranexamic Acid + Normal Saline (NCT06638749)
- 2024-10-15Phase 3 first posted: University of Kansas Medical Center, Tranexamic Acid + Normal Saline (NCT06638749)
- 2024-10-10Results posted on the registry: Lancaster General Hospital, Tranexamic Acid Injectable Solution (NCT03923959)
- 2024-10-02Phase 3 first posted: Hamilton Health Sciences Corporation, Before CPB Tranexamic Acid + After CPB Tranexamic Acid (NCT06622564)
- 2024-10-01Phase 3 first posted: Campbell Clinic, Tranexamic acid + Placebo (NCT06618820)
- 2024-08-07Also stopped (withdrawn): University of California, San Francisco, Defibrotide (NCT06182410)
- 2024-08-06Results posted on the registry: University of Birmingham, a drug against PLG (NCT04341662)
- 2024-08-01Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Tranexamic Acid (NCT03413891)
- 2024-08-01Also stopped (terminated): Universitaire Ziekenhuizen KU Leuven, Tranexamic Acid (NCT03413891)
- 2024-07-25Phase 3 first posted: London School of Hygiene and Tropical Medicine, Tranexamic Acid 500 MG + Placebo (NCT06519422)
- 2024-07-23Also stopped (withdrawn): Northwestern University, Tranexamic acid injection (NCT04724772)
- 2024-07-01Results posted on the registry: Margaret Ragni, recombinant von Willebrand factor + tranexamic acid (NCT02606045)
- 2024-07-01Also stopped (terminated): Margaret Ragni, recombinant von Willebrand factor + tranexamic acid (NCT02606045)
- 2024-06-26Results posted on the registry: NYU Langone Health, Tranexamic acid + Aminocaproic acid (NCT04814433)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision